Songjiang Ma and Yueying Zhu Report 6.33% Stake in Gyre Therapeutics Following Cullgen Merger

This Amendment No. 1 to Schedule 13D was filed by Songjiang Ma and his spouse, Yueying Zhu, regarding their holdings in Gyre Therapeutics, Inc. (GYRE). The filing reports a beneficial ownership of 7,342,131 shares, representing approximately 6.33% of the company's common stock. This total includes 2,806,084 shares held directly by Ms. Zhu and 4,536,047 shares underlying options held by Mr. Ma that are exercisable within 60 days. The amendment was primarily prompted by changes in the total number of shares outstanding following Gyre's acquisition of Cullgen Inc., which closed on May 4, 2026. The merger was an all-stock transaction valued at approximately $300 million. While the reporting persons did not receive additional securities in the merger, the transaction altered the denominator for ownership percentage calculations. The company has scheduled a stockholder meeting for June 10, 2026, to vote on the conversion of Series B Preferred Stock issued during the merger into common stock.